Beneficial effects of oral Iron in Japanese patients on hemodialysis

Internal Medicine

Volumn 56, Issue 18, 2017, Pages 2395-2399

  Sanai, Toru ^a   Ono, Takashi ^a   Fukumitsu, Toma ^a  

^a Fukumitsu Hospital   (Japan)

Author keywords

Ferritin; Hemodialysis (HD); Iron (Fe); Iron deficiency anemia (IDA); Oral iron; Transferrin saturation (TSAT)

Indexed keywords

ANTIANEMIC AGENT; CALCIUM; FERRITIN; FERROMIA; HEMOGLOBIN; NITROGEN; PHOSPHATE; SERUM ALBUMIN; SODIUM FERROUS CITRATE; TRANSFERRIN; UNCLASSIFIED DRUG; UREA; BIOLOGICAL MARKER; ERYTHROPOIETIN; FERROUS ION; IRON; MONOFERROUS ACID CITRATE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; END STAGE RENAL DISEASE; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BINDING CAPACITY; IRON DEFICIENCY ANEMIA; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; TRANSFERRIN BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; JAPAN; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; BIOMARKERS; ERYTHROPOIETIN; FEMALE; FERRITINS; FERROUS COMPOUNDS; HEMATOCRIT; HEMOGLOBINS; HUMANS; IRON; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TRANSFERRIN;

EID: 85029644978     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.8520-16     Document Type: Article

References (25)

1. Levey AS, Eckardt K-U, Tsukamoto Y, et al. Definition and classification chronic kidney disease: A position statement from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089-2100, 2005.
2. Masakane I, Nakai S, Ogata S, et al. An overview of regular dialysis treatment in Japan (as of December 31, 2014). J Jpn Soc Dial Ther 49: 1-34, 2016 (in Japanese).
3. Lazarus JM, Lowrie G, Hampaers CL, Merrill JP. Cardiovascular disease in uremic patients on hemodialysis. Kidney Int 7 (Suppl): 167-175, 1975.
4. Okada M, Imamura K, Iida M, Omae T. Hypophosphatemia induced by intravenous administration of saccharated iron oxide. Klin Wochenshr 61: 99-102, 1983.
5. Imamura K. Effects intravenous administration of iron preparation on the metabolism of phosphorus. Fukuoka Acta Med 75: 316-326, 1984.
6. Okada M, Imamura K, Fuchigami T, et al. Osteomalacia caused by intravenous administration saccharated ferric oxide for treatment of iron deficiency anemia associated with nonspecific multiple ulcers of the small intestine: report of two cases. Jpn J Intern Med 71: 1566-1572, 1982 (in Japanese, Abstract in English).
7. Sato K, Shiraki M. Saccharated ferric oxide-induced osteopathy due to nephropathy. Endocrine J 45: 431-439, 1998.
8. Suzuki A, Ohike H, Matsuoka Y, Irimajiri S. Iatrogenic osteomalacia caused by intravenous administration of saccharated ferric oxide. Am J Hematol 43: 75-76, 1993.
9. Sato K, Nohtomo K, Demura H. Saccharated ferric oxide (SFO) -induced ostemalacia: In vitro inhibition by SFO of bone formation and 1, 25 - dihydroxy-vitamin D production in renal tubules. Bone 21: 57-64, 1997.
10. Sanai T, Oochi N, Okada M, Imamura K, Okuda S, Iida M. Effect of saccharated iron oxide and iron dextran on the metabolism of phosphorus in rats. J Lab Clin Med 146: 25-29, 2005.
11. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65: 2279-2289, 2004.
12. Zager RA, Johson AC, Hanson SY. Parenteral iron nephrotoxicity: Potential mechanisms and consequences. Kidney Int 66: 144-156, 2004.
13. Lim CS, Vaziri ND. The effect of iron dextran on the oxidative in cardiovascular tissues of rats with chronic renal failure. Kidney Int 65: 1802-1809, 2004.
14. Horl WH. Should we still use iron dextran in hemodialysis patients? Am J Kidney Dis 37: 859-861, 2001.
15. Fiahbane S. Safety in iron management. Am J Kidney Dis 41 (Suppl 5): 18-27, 2003.
16. Zager RA, Johson AC, Hanson SY, Wasse H. Parenteral iron formulation: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40: 90-103, 2002.
17. Kuroda S, Komori M, Nagamatsu K, et al. Effect of iron as a new type of phosphate binder in hemodialysis patients. Jpn J Nephrol 37: 468-473, 1995.
18. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 88: 905-914, 2015.
19. Granick S. Protein apoferritin and ferritin in iron feeding and absorption. Science 103: 107, 1946.
20. Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A. Intravenous iron versus oral iron supplementation for the treatment of anemia in CKD: a updated systematic review and meta-analysis. Am J Kidney Dis 68: 677-690, 2016.
21. Kuragano T, Shimonaka Y, Kida A, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol 31: 534-540, 2010.
22. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferrorportin and inducing its internali-zation. Science 306: 2090-2093, 2004.
23. Shimizu Y, Tada Y, Yamauchi M, et al. Hypophosphatemia induced intravenous administration of saccharated ferric oxide: Another form of FGF23-related hypophosphatemia. Bone 45: 814-816, 2009.
24. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: A prospective study. J Clin Endocrinol Metab 94: 2332-2337, 2009.
25. Yokoyama K, Akiba T, Fukagawa M, et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant 29: 1053-1060, 2014.